Gene therapy of cancer.
Rosenberg
S A
SA
D000818:Animals; D002985:Clinical Protocols; D016207:Cytokines / Q000235:genetics / Q000627:therapeutic use; D004274:DNA, Recombinant / Q000235:genetics; D005818:Genetic Engineering; D005819:Genetic Markers; D015316:Genetic Therapy; D005822:Genetic Vectors; D006805:Human Experimentation; D006801:Humans; D007155:Immunologic Factors / Q000235:genetics / Q000627:therapeutic use; D016219:Immunotherapy, Adoptive; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology / Q000637:transplantation; D008545:Melanoma / Q000276:immunology / Q000473:pathology / Q000628:therapy; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy; D011948:Receptors, Antigen, T-Cell / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000627:therapeutic use; D014162:Transfection; D014170:Transformation, Genetic; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000627:therapeutic use
D016207:Cytokines; D004274:DNA, Recombinant; D005819:Genetic Markers; D007155:Immunologic Factors; D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha